Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.09
TMO's Cash to Debt is ranked lower than
51% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. TMO: 0.09 )
TMO' s 10-Year Cash to Debt Range
Min: 0.09   Max: 2.13
Current: 0.09

0.09
2.13
Equity to Asset 0.48
TMO's Equity to Asset is ranked higher than
62% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. TMO: 0.48 )
TMO' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.75
Current: 0.48

0.35
0.75
Interest Coverage 5.22
TMO's Interest Coverage is ranked higher than
50% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. TMO: 5.22 )
TMO' s 10-Year Interest Coverage Range
Min: 3.21   Max: 21.63
Current: 5.22

3.21
21.63
F-Score: 7
Z-Score: 2.39
M-Score: -2.28
WACC vs ROIC
8.44%
7.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.82
TMO's Operating margin (%) is ranked higher than
92% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. TMO: 14.82 )
TMO' s 10-Year Operating margin (%) Range
Min: 1.56   Max: 14.82
Current: 14.82

1.56
14.82
Net-margin (%) 11.22
TMO's Net-margin (%) is ranked higher than
93% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.38 vs. TMO: 11.22 )
TMO' s 10-Year Net-margin (%) Range
Min: -7.07   Max: 16.75
Current: 11.22

-7.07
16.75
ROE (%) 9.57
TMO's ROE (%) is ranked higher than
84% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. TMO: 9.57 )
TMO' s 10-Year ROE (%) Range
Min: -8.18   Max: 15.73
Current: 9.57

-8.18
15.73
ROA (%) 4.56
TMO's ROA (%) is ranked higher than
83% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. TMO: 4.56 )
TMO' s 10-Year ROA (%) Range
Min: -3.29   Max: 10.39
Current: 4.56

-3.29
10.39
ROC (Joel Greenblatt) (%) 56.12
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. TMO: 56.12 )
TMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.07   Max: 61.38
Current: 56.12

4.07
61.38
Revenue Growth (3Y)(%) 11.80
TMO's Revenue Growth (3Y)(%) is ranked higher than
89% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TMO: 11.80 )
TMO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.9   Max: 18.7
Current: 11.8

-12.9
18.7
EBITDA Growth (3Y)(%) 23.40
TMO's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. TMO: 23.40 )
TMO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30   Max: 40.8
Current: 23.4

-30
40.8
EPS Growth (3Y)(%) 21.00
TMO's EPS Growth (3Y)(%) is ranked higher than
89% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. TMO: 21.00 )
TMO' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.3   Max: 74.6
Current: 21

-41.3
74.6
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TMO Guru Trades in Q1 2014

Ruane Cunniff 2,551 sh (New)
Paul Tudor Jones 9,135 sh (New)
Signature Select Canadian Fund 88,800 sh (New)
Ray Dalio 42,130 sh (New)
Bill Frels 1,910 sh (New)
PRIMECAP Management 3,561,800 sh (+656.22%)
David Dreman 23,488 sh (+63.79%)
Larry Robbins 9,560,893 sh (+12.02%)
Leon Cooperman 847,800 sh (+2.76%)
Jean-Marie Eveillard 200 sh (unchged)
Louis Moore Bacon 4,989 sh (unchged)
Caxton Associates Sold Out
Pioneer Investments 1,850,854 sh (-2.63%)
John Paulson 4,555,000 sh (-3.09%)
Scott Black 110,672 sh (-6.66%)
Andreas Halvorsen 9,668,639 sh (-6.81%)
Steven Romick 3,315,000 sh (-10.28%)
First Pacific Advisors 3,509,100 sh (-10.30%)
Dodge & Cox 86,702 sh (-12.34%)
John Griffin 2,925,000 sh (-14.60%)
John Rogers 556,094 sh (-34.32%)
Jeremy Grantham 18,200 sh (-58.22%)
Steven Cohen 99,472 sh (-58.90%)
» More
Q2 2014

TMO Guru Trades in Q2 2014

Eric Mindich 432,000 sh (New)
Ruane Cunniff 3,101 sh (+21.56%)
Larry Robbins 10,942,193 sh (+14.45%)
PRIMECAP Management 3,962,230 sh (+11.24%)
Leon Cooperman 898,800 sh (+6.02%)
Pioneer Investments 1,923,572 sh (+3.93%)
First Pacific Advisors 3,521,200 sh (+0.34%)
Steven Cohen 148,400 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Steven Romick 3,315,000 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Jeremy Grantham Sold Out
John Rogers 536,928 sh (-3.45%)
Bill Frels 1,785 sh (-6.54%)
Dodge & Cox 81,002 sh (-6.57%)
John Griffin 2,715,000 sh (-7.18%)
Andreas Halvorsen 8,271,280 sh (-14.45%)
Scott Black 79,652 sh (-28.03%)
John Paulson 3,225,000 sh (-29.20%)
Paul Tudor Jones 6,390 sh (-30.05%)
David Dreman 16,420 sh (-30.09%)
» More
Q3 2014

TMO Guru Trades in Q3 2014

Caxton Associates 45,000 sh (New)
Vanguard Health Care Fund 1,494,300 sh (New)
Joel Greenblatt 3,314 sh (New)
Jim Simons 37,844 sh (New)
Eric Mindich 1,119,000 sh (+159.03%)
Signature Select Canadian Fund 122,600 sh (+38.06%)
Bill Frels 2,381 sh (+33.39%)
PRIMECAP Management 4,308,150 sh (+8.73%)
Larry Robbins 11,375,667 sh (+3.96%)
First Pacific Advisors 3,549,700 sh (+0.81%)
John Rogers 540,702 sh (+0.70%)
Jean-Marie Eveillard 200 sh (unchged)
Ruane Cunniff 3,101 sh (unchged)
Steven Romick 3,315,000 sh (unchged)
Pioneer Investments 1,985,531 sh (unchged)
John Griffin 2,715,000 sh (unchged)
John Paulson Sold Out
Scott Black 79,249 sh (-0.51%)
David Dreman 16,213 sh (-1.26%)
Andreas Halvorsen 7,976,502 sh (-3.56%)
Leon Cooperman 864,000 sh (-3.87%)
Dodge & Cox 57,082 sh (-29.53%)
Steven Cohen 79,800 sh (-46.23%)
Paul Tudor Jones 3,200 sh (-49.92%)
» More
Q4 2014

TMO Guru Trades in Q4 2014

Ray Dalio 11,899 sh (New)
Mario Gabelli 13,000 sh (New)
Jim Simons 206,644 sh (+446.04%)
Steven Cohen 239,700 sh (+200.38%)
Paul Tudor Jones 4,763 sh (+48.84%)
Vanguard Health Care Fund 2,179,000 sh (+45.82%)
Eric Mindich 1,563,000 sh (+39.68%)
John Rogers 580,501 sh (+7.36%)
PRIMECAP Management 4,487,090 sh (+4.15%)
Bill Frels 2,446 sh (+2.73%)
Steven Romick 3,381,300 sh (+2.00%)
First Pacific Advisors 3,617,400 sh (+1.91%)
Larry Robbins 11,387,265 sh (+0.10%)
Jean-Marie Eveillard 200 sh (unchged)
Leon Cooperman Sold Out
Joel Greenblatt Sold Out
Caxton Associates Sold Out
Pioneer Investments 1,965,136 sh (-1.03%)
David Dreman 15,984 sh (-1.41%)
Dodge & Cox 56,202 sh (-1.54%)
Scott Black 74,862 sh (-5.54%)
Ruane Cunniff 2,873 sh (-7.35%)
John Griffin 2,115,000 sh (-22.10%)
Andreas Halvorsen 5,786,510 sh (-27.46%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc. - May 07, 2014

In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc.
In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future. Read more...
Steven Romick's Top Five Highlight Technology Sector
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.40
TMO's P/E(ttm) is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 28.40 )
TMO' s 10-Year P/E(ttm) Range
Min: 11.11   Max: 55.16
Current: 28.4

11.11
55.16
Forward P/E 16.23
TMO's Forward P/E is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 16.23 )
N/A
PE(NRI) 28.40
TMO's PE(NRI) is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 28.40 )
TMO' s 10-Year PE(NRI) Range
Min: 13.48   Max: 54.55
Current: 28.4

13.48
54.55
P/B 2.60
TMO's P/B is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.82 vs. TMO: 2.60 )
TMO' s 10-Year P/B Range
Min: 0.5   Max: 2.67
Current: 2.6

0.5
2.67
P/S 3.19
TMO's P/S is ranked higher than
74% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.63 vs. TMO: 3.19 )
TMO' s 10-Year P/S Range
Min: 1.24   Max: 3.48
Current: 3.19

1.24
3.48
PFCF 24.62
TMO's PFCF is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 24.62 )
TMO' s 10-Year PFCF Range
Min: 10.22   Max: 32.28
Current: 24.62

10.22
32.28
POCF 20.63
TMO's POCF is ranked higher than
86% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 431.57 vs. TMO: 20.63 )
TMO' s 10-Year POCF Range
Min: 8.72   Max: 26.55
Current: 20.63

8.72
26.55
EV-to-EBIT 26.47
TMO's EV-to-EBIT is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 26.47 )
TMO' s 10-Year EV-to-EBIT Range
Min: 11.2   Max: 73.5
Current: 26.47

11.2
73.5
PEG 1.56
TMO's PEG is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 1.56 )
TMO' s 10-Year PEG Range
Min: 0.56   Max: 11.39
Current: 1.56

0.56
11.39
Shiller P/E 40.33
TMO's Shiller P/E is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 40.33 )
TMO' s 10-Year Shiller P/E Range
Min: 16.99   Max: 66.69
Current: 40.33

16.99
66.69
Current Ratio 1.22
TMO's Current Ratio is ranked higher than
54% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. TMO: 1.22 )
TMO' s 10-Year Current Ratio Range
Min: 1.22   Max: 3.83
Current: 1.22

1.22
3.83
Quick Ratio 0.87
TMO's Quick Ratio is ranked higher than
54% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. TMO: 0.87 )
TMO' s 10-Year Quick Ratio Range
Min: 0.87   Max: 3.4
Current: 0.87

0.87
3.4
Days Inventory 71.95
TMO's Days Inventory is ranked higher than
81% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. TMO: 71.95 )
TMO' s 10-Year Days Inventory Range
Min: 65.13   Max: 183.33
Current: 71.95

65.13
183.33
Days Sales Outstanding 53.46
TMO's Days Sales Outstanding is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 74.31 vs. TMO: 53.46 )
TMO' s 10-Year Days Sales Outstanding Range
Min: 50.89   Max: 159.82
Current: 53.46

50.89
159.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.45
TMO's Dividend Yield is ranked lower than
86% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. TMO: 0.45 )
TMO' s 10-Year Dividend Yield Range
Min: 0.22   Max: 0.86
Current: 0.45

0.22
0.86
Dividend Payout 0.13
TMO's Dividend Payout is ranked higher than
98% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 0.13 )
TMO' s 10-Year Dividend Payout Range
Min: 0.13   Max: 0.17
Current: 0.13

0.13
0.17
Yield on cost (5-Year) 0.40
TMO's Yield on cost (5-Year) is ranked lower than
88% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. TMO: 0.40 )
TMO' s 10-Year Yield on cost (5-Year) Range
Min: 0.22   Max: 0.86
Current: 0.4

0.22
0.86
Share Buyback Rate -1.50
TMO's Share Buyback Rate is ranked higher than
77% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.50 vs. TMO: -1.50 )
TMO' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -38.3
Current: -1.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.33
TMO's Price/DCF (Projected) is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 1.33 )
TMO' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 14.42
Current: 1.33

0.6
14.42
Price/Median PS Value 1.46
TMO's Price/Median PS Value is ranked higher than
65% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. TMO: 1.46 )
TMO' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 1.43
Current: 1.46

0.38
1.43
Price/Peter Lynch Fair Value 1.56
TMO's Price/Peter Lynch Fair Value is ranked higher than
97% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 1.56 )
TMO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.63   Max: 2.42
Current: 1.56

0.63
2.42
Earnings Yield (Greenblatt) 3.80
TMO's Earnings Yield (Greenblatt) is ranked higher than
82% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TMO: 3.80 )
TMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 8.9
Current: 3.8

1.4
8.9
Forward Rate of Return (Yacktman) 21.53
TMO's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. TMO: 21.53 )
TMO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.2   Max: 34.8
Current: 21.53

-19.2
34.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, COO, ISRG » details
Traded in other countries:TN8.Germany, TMO.Mexico,
Thermo Fisher Scientific Inc is a Delaware corporation and was incorporated in 1956. The Company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It serves more than 400,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company serves their customers through four brands, Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
The Gurus to Follow Based on Sector — Part 2 Dec 09 2014 
Glenview's Larry Robbins Adds to Stake in Watchmaker Fossil Sep 15 2014 
John Rogers Comments on Thermo Fisher Scientific Inc. May 07 2014 
John Rogers' Ariel Appreciation Fund First Quarter 2014 Commentary Apr 30 2014 
Steven Romick's Top Five Highlight Technology Sector Apr 16 2014 
Different Opinions on Bio-Rad Laboratories Apr 03 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 10 2014 
Steven Romick’s Top Five Q4 Holdings Jan 14 2014 

More From Other Websites
SelectScience Community Chooses Thermo Fisher Scientific for Two Awards Mar 11 2015
Coverage initiated on Thermo Fisher by UBS Mar 10 2015
Lightning Round: A mistake to turn on this sector Mar 09 2015
Thermo Fisher Scientific Strengthens Technology Leadership in Applied Markets at Pittcon 2015 Mar 09 2015
Fully Integrated Informatics Solution is All-in-One Platform for Managing Today’s Labs Mar 09 2015
Thermo Fisher Scientific Declares Quarterly Dividend Mar 09 2015
Thermo Fisher Scientific Strengthens Technology Leadership in Applied Markets at Pittcon 2015 Mar 09 2015
New Online Repository Provides Instant and Free Access to Hundreds of Full Analytical Methods Mar 09 2015
Transformative UHPLC System Showcases Performance and Throughput Mar 09 2015
New HRAM System Makes Orbitrap Technology More Widely Accessible Mar 09 2015
New Personal Dust Monitor Designed to Help Reduce Miners’ Exposure to Coal Dust Mar 06 2015
New Handheld Analyzer Combines FTIR and Raman Technologies for Military, Explosives and Hazmat... Mar 06 2015
THERMO FISHER SCIENTIFIC INC. Files SEC form 10-K/A, Annual Report Mar 05 2015
THERMO FISHER SCIENTIFIC INC. Financials Mar 05 2015
New Conveyor System for Metal Detector Line Designed to Maximize Efficiency Mar 05 2015
10-K for Thermo Fisher Scientific, Inc. Feb 28 2015
Omega Advisors exits position in Thermo Fisher Scientific Feb 27 2015
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Feb 26 2015
Thermo Fisher Scientific to Present at the Cowen and Company 35th Annual Health Care Conference on... Feb 26 2015
Thermo Fisher Scientific Declares Quarterly Dividend Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK